EGFR and head and neck squamous cell carcinoma: To date, there are no biomarkers used in clinical practice that can predict tumor response to cetuximab in HNSCC patients despite predictive biomarkers for response to EGFR inhibitors being well established in non-small cell lung cancer (NSCLC) (37) and colorectal cancer (CRC) (38).